Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment ...

Egypt has warned that an expulsion of Palestinians would destabilize the region and undermine its peace treaty with Israel.

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...